CD248 and neoplasm: Chacko et al. radiolabeled MORAb-004 with 124I and confirmed its specific and sensitive binding with endosialin-positive cells and demonstrated that radiolabeled MORAb-004 could be specifically and sensitively taken up by endosialin-positive tumors in vivo, suggesting that it could be clinically used for immuno-PET to assess endosialin-positive tumor status 92.